Part II: Granulocyte-Colony Stimulating Factor Adjunct Therapy for Biliary Atresia
Status:
Recruiting
Trial end date:
2024-10-31
Target enrollment:
Participant gender:
Summary
The Investigators propose to test the hypothesis that GCSF enhances the clinical outcome of
biliary atresia in a multi-institutional Phase 2 trial to prospectively evaluate the safety
and efficacy of GCSF in each of the 2 groups of newly diagnosed BA patients: KBA (i.e.,
Kasai-operated) or NoK (i.e., patients who did not undergo Kasai surgery). Subjects who
participate in the trial will be followed for 2 years.